Bavel Health: Accelerating insights in clinical studies
Bavel Health is a healthcare data insights company that operates a state-of-the art
global Healthcare Data Exchange & Insights platform connecting hospitals and
researchers. This platform provides access to large, anonymized patient-level
datasets under strict privacy and security controls, for pharmaceutical and drug
development companies, data access companies, start-ups, academia and
governments. Bavel Health’s exchange offers an unmatched source of real-world
clinical data combined with advanced analytics capabilities. By leveraging this
network, pharmaceutical companies and data researchers can quickly and securely
explore real-world evidence, driving accelerated insights while ensuring compliance.
Bavel Health’s analytics competence enables the development of hypotheses, the
formulation of potential biomarkers and the refinement and validation of those
hypotheses and potential biomarkers for clinical studies, with real anonymised
patient datasets.
From Semi Real-World Data to Real-World Data
Bavel Health employs a two-stage analytics process to help clients move from initial
questions to validated answers efficiently:
1. Preliminary analysis with Semi Real-World Data: In the first phase, Bavel
generates synthetic data that represents the target Real-World Data which is
not random, and statistically mirrors real patient populations but contains no
actual patient information. Analysts run initial queries on this aggregate-
matched synthetic dataset to get quick, indicative results. Because the data is
collected from routine clinical practice outside of controlled clinical trials - such
as information from electronic health records, insurance claims, patient
registries, and wearable devices, early exploration can happen immediately,
with no privacy risk or waiting for approvals. Clients rapidly test hypotheses
and refine questions in this sandbox environment, often obtaining preliminary
answers in days or hours instead of months.
2. Validation with Real-World Data: Once the approach is refined using Semi
Real-world Data, Bavel seamlessly transitions to the Real-World Data phase.
In this second stage, the analysis is run on actual de-identified and linked
patient records drawn from Bavel’s global Healthcare Data Exchange network
of hospital data lakes. This step provides conclusive insights and real-world
evidence with true patient data. By the time clients reach this phase, they
have well-defined queries, ensuring the use of real data is justified and
impactful. The result is validated insights backed by large-scale real
healthcare datasets, ready to inform decisions or regulatory submissions.
For both stages, Bavel Health offers Concierge Services that provide scientific
advice and technical support to guide our clients to formulate the right and precise
questions for a given dataset. Consequently, more accurate and relevant analyses
can be performed in the requested specific data insight report. The Concierge
[Link]
Services team at Bavel Health has years of experience and specialized expertise in
clinical research.
Key benefits
● Faster insights and decisions: By starting with readily available Real-World
Data, clinical teams can obtain preliminary results in days instead of waiting
months for Real-World Data access. This accelerated insight means quicker
go/no-go decisions for research ideas, clinical trial plans, or market strategies.
Early analytic cycles that once took weeks can be compressed into mere
hours, significantly speeding up time-to-decision.
● Privacy-safe exploration: All initial analysis occurs in a secure Semi-Real
World Data sandbox with no real patient information, eliminating privacy risks
in early stages. Sensitive questions can be explored without compliance
hurdles because no actual patients are involved. This privacy-by-design
approach means analysts don’t need lengthy ethics approvals to start, and
stakeholders can freely collaborate on hypotheses knowing patient
confidentiality is fully protected.
● Efficient use of resources: Bavel’s model ensures that heavy lifting with
Real-World Data is done only when necessary. The use of aggregate-
matched Semi Real-World Data in the first stage avoids expending major
effort on Real-World Data access and preparation for ideas that might not pan
out. Data science teams can focus their time and computing resources on the
most promising questions, improving ROI on analytics.
● Access to diverse Real-World Data: When moving to the Real Data phase,
clinical teams tap into Bavel’s extensive global data exchange network. This
provides access to a federated pool of de-identified health records from
multiple hospitals and regions, rather than a single source. The Real-World
datasets are high-quality (drawn directly from electronic health records) and
can cover millions of patients across diverse demographics and care settings.
Such breadth and diversity lead to more robust and generalizable insights,
which is crucial for developing drugs that perform across a wide range of
populations. This network approach also simplifies data acquisition: through
one platform, clients can query a world of data without negotiating individual
data-sharing agreements.
Clinical teams: Use cases and applications
Bavel Health’s two-stage analytics and data sharing and learning capabilities support
a range of high-value applications for pharmaceutical companies:
[Link]
● Real-World Evidence (RWE) generation: With access to broad Real-World
datasets, pharmaceutical companies can efficiently generate evidence on
drug outcomes, safety, and utilization in actual clinical practice. Early
analyses on representative data help identify trends or signals, which are then
confirmed with real patient data to produce credible RWE. This approach
accelerates studies for regulatory submissions, health economics and
outcome research and publication, by quickly honing-in on relevant insights
and then backing them with hard evidence from real-world populations.
● Clinical trial design & feasibility: Bavel’s Semi-Real World Data enables
teams to simulate trial scenarios and assess feasibility before investing in a
real trial. Researchers can realistically model patient eligibility criteria,
enrollment rates, or endpoints using Semi-Real World patient cohorts,
identifying potential challenges early. If the “trial run” looks promising, the
Real-World Data network can then provide exact patient counts and
characteristics to validate feasibility. This two-step method helps optimize
protocol design, site selection, and recruitment strategies, ultimately
improving trial success rates and reducing costly amendments. Sponsors can
confidently plan trials knowing the design is grounded in data-driven insights.
● Post-market surveillance: After a drug is launched, Bavel’s state-of-the art
platform helps monitor its performance and safety across large patient
populations. Clinical safety teams can explore adverse event signals or
outcome trends in the aggregate-matched synthetic data without exposing
any patient information. Once a potential safety signal or usage pattern is
identified, it can be investigated with actual Real-World Data from the
exchange to confirm if it’s a true concern. This proactive surveillance
approach supports pharmacovigilance by quickly flagging issues and
validating them with robust data, all while maintaining patient privacy. It also
allows tracking of long-term effectiveness and comparative outcomes for
therapies in the real world, providing insights for label updates or risk
management as needed.
By combining a privacy-preserving exploratory phase with access to rich Real-World
Data, Bavel Health’s data analytics approach enables Life Sciences and clinical
research teams to go from initial question to conclusive evidence faster and more
cost-effectively than traditional methods, and with no or minimal privacy and security
risks. Clients gain a strategic edge: they can identify opportunities, de-risk decisions,
and generate credible Real-World insights with unprecedented efficiency. The result
is a more agile research and development process, where ideas can be tested
quickly and the best ones validated on a global scale of patient data, safeguarding
privacy and unlocking the full value of patient data.
[Link]
